Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact
Seeking Low-Cost Practical Option For Sub-Saharan Africa
Executive Summary
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
You may also be interested in...
Big Pharmas Back $300m Neglected Disease Fund
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.
Bluebird Sickle Cell Gene Therapy Hangs In Balance
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
Sickle Cell And Beta-Thalassemia Bend To Gene Manipulation By CRISPR/Vertex And Bluebird
Data for new genetic methods to tackle severe hemoglobinopathies presented at the EHA meeting bring more confidence for bluebird’s gene therapy LentiGlobin and early suggestions of a functional cure with CRISPR gene editing with CRISPR Therapeutics/Vertex’s CTX001.